Immunoglobulin superfamily 11 (IgSF11) overexpression has been observed in several cancer types, including gastric cancer, hepatocellular carcinoma, colorectal cancers and gliomas, and linked to aggressive clinicopathological features. Therefore, IgSF11 has been proposed as a novel immune checkpoint ligand and a candidate for cancer immunotherapy. However, the potential role and clinical significance of IgSF11 in human breast cancer remain unexplored.

IMU Biosciences Ltd. is working to transform society’s understanding of the immune system. The company’s platform maps the immune system at molecular, cellular and system levels, to unlock new insights into immune-related health and diseases, paving the way for clinical applications that could improve patient outcomes.

Aptevo Therapeutics Inc. has unveiled two new trispecific candidates, APVO-452 for prostate cancer and APVO-451 for solid tumors. Powered by the company’s Adaptir-Flex platform, each trispecific immune cell engager biologic brings together tumor targeting, T-cell activation and immune costimulation in a single molecule.

Two independent studies have linked neuronal injury, inside or outside the brain, to cancer progression and offer new biomarkers and strategies for prevention. While cerebral cancer cells damage axons and drive tumor development, in other types of cancer affecting other organs, nerve disruption caused by tumor proximity triggers inflammation and a suppressive environment that may also be associated with immunotherapy resistance.

Tidewave Bio has completed an FDA Interact meeting that provided regulatory feedback as the company advances its lead program, TBC-1, toward IND-enabling studies. The company is developing a universal, off-the-shelf immunotherapy platform that is converted into a patient-specific precision medicine in real time using a tumor biopsy.

Two independent studies have linked neuronal injury, inside or outside the brain, to cancer progression and offer new biomarkers and strategies for prevention. While cerebral cancer cells damage axons and drive tumor development, in other types of cancer affecting other organs, nerve disruption caused by tumor proximity triggers inflammation and a suppressive environment that may also be associated with immunotherapy resistance.

Spica Therapeutics NV has been awarded a 2-year €1.0 million (US$1.2 million) grant from Flanders Innovation & Entrepreneurship (VLAIO) to accelerate the development of the company’s lead anti-CD163 depleting monoclonal antibody program in oncology, advancing it toward early IND-enabling studies.

HCW Biologics Inc. has outlined its development of second-generation, pembrolizumab-based immunotherapeutics against solid tumors, particularly for pancreatic and ovarian cancer, using its proprietary T-cell Receptor β Chain constant region (TRBC) product discovery and development platform technology.